Mitotic activity and bone marro ...
The purpose of this article is to investigate the prognostic value of the mitotic activity index (MAI) and the presence of disseminated tumor cells ...
Association between polymorphis ...
Epidemiological studies have evaluated the association between ataxia telangiectasia mutated (ATM) gene polymorphisms and breast cancer risk. Howeve ...
Breast cancer screening in BRCA ...
Breast cancer screening is offered to BRCA1 and BRCA2 mutation carriers from the age of 25 years because of their increased risk of breast cancer. A ...
Letrozole plus GnRH analogue as ...
Patients with large ER positive tumors candidate to preoperative chemotherapy may also benefit from a concurrent endocrine intervention, but this is ...
Epirubicin and paclitaxel with ...
An increased dose-intensity can be achieved by either higher dose of chemotherapy per cycle (dose-escalation) or by shortening the interval between ...
Evidence on the association bet ...
Several molecular epidemiological studies were conducted in recent years to evaluate the association between NQO1 Pro187Ser polymorphism and breast ...
Concurrent use of tamoxifen wit ...
Concurrent use of tamoxifen and cytochrome P450 2D6 (CYP2D6) inhibitors, such as selective serotonin reuptake inhibitors, has been shown to decrease ...
Socioeconomic differences in su ...
There seem to be socioeconomically differences in survival for females with breast cancer, usually associated with a higher stage of disease. Howeve ...
Associations among baseline var ...
Provision of social support and rehabilitation for patients with physical, mental, and functional problems after cancer treatment is important for l ...
Anastrozole and letrozole: an i ...
Previous studies have demonstrated that both anastrozole and letrozole are well tolerated. Letrozole suppresses estrogen to a greater degree than an ...
Health-related quality of life ...
To investigate whether the health-related quality of life (HRQOL) of patients switching from tamoxifen to anastrozole in a randomized trial is ident ...
Impact of treatment characteris ...
Pathological complete response (pCR) to neoadjuvant treatment correlates with outcome in breast cancer. We determined whether characteristics of neo ...
Increased overall survival inde ...
Recent studies have reported the potential clinical utility for metastatic breast cancer (MBC) patients of continuing trastuzumab beyond progression ...
Effect of aspirin and other NSA ...
Aspirin and other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit aromatase activity and thus could selectively lower inciden ...
Characterizing the impact of 25 ...
The significant increase in the detection and treatment of ductal carcinoma in situ (DCIS) since the introduction of screening mammography has not b ...
Monthly versus 3-monthly gosere ...
This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (ZoladexTM) injection with the current 3.6 mg monthly dose in pre ...
Evaluation of the association o ...
Trastuzumab (T) is effective in metastatic breast cancer (MBC) with HER2 overexpression and/or amplification, but resistance to T develops in a sign ...
Accuracy of unidimensional and ...
Pathological complete response (pCR) is an important predictor of long-term survival in patients with breast cancer receiving neoadjuvant chemothera ...
Lack of association between ATM ...
Epidemiological studies have evaluated the association between ATM C.1066-6T[G (IVS10-6T[G) mutation and breast cancer risk. However, the results re ...
Spectrum of BRCA1/2 point mutat ...
The distribution of BRCA1/2 germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean populati ...
Disparities in breast cancer ch ...
Disparities in breast cancer stage and mortality by race/ethnicity in the United States are persistent and well known. However, few studies have ass ...
Occult breast carcinoma in brea ...
Breast reduction is a common surgical procedure performed by plastic and oncoplastic breast surgeons. The authors report on the incidence and manage ...
One size does not fit all: qual ...
Adjuvant endocrine therapy for breast cancer is associated with significant improvements in disease-related outcomes. Five years of tamoxifen therap ...
Docetaxel metabolism is not alt ...
Docetaxel is primarily metabolized by CYP3A4 and susceptible to alterations in clearance by CYP3A4 inhibition and induction. Imatinib is a CYP3A4 in ...
Multiple biomarker expression o ...
Patients with locally advanced/inflammatory breast cancer (LABC/IBC) face a high likelyhood of recurrence and prognosis for relapsed, or de novo sta ...